Frankfurt
28.07.25 | 08:14
4,920 Euro
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 04.07. | Nxera Pharma To Receive $4.8 Mln Milestone As Centessa Advances ORX142 To Phase 1 Study | 2 | RTTNews | ||
| 04.07. | Nxera Pharma to Receive US$4.8 Million in Milestone Payments Following Centessa's Initiation of Clinical Development of ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist | 138 | GlobeNewswire (Europe) | Tokyo, Japan and Cambridge, UK, 4 July 2025 - Nxera Pharma Co., Ltd. ("Nxera" or "the Company"; TSE 4565) today announces that it will receive US$4.8 million in milestone payments from Centessa Pharmaceuticals... ► Artikel lesen | |
| 03.06. | Nxera Hits Important Milestone in Diabetes Drug Partnership with Eli Lilly | 9 | Insider Monkey | ||
| 03.06. | Nxera Pharma to Receive US$15 Million from Neurocrine Biosciences Following Dosing of First Patient in Phase 3 Trial of NBI-1117568 | 150 | GlobeNewswire (Europe) | Tokyo, Japan and Cambridge, UK, 3 June 2025 - Nxera Pharma Co., Ltd. ("Nxera" or "the Company"; TSE 4565) today announces that its partner, Neurocrine Biosciences ("Neurocrine") has dosed the first... ► Artikel lesen | |
| 02.06. | Nxera Pharma Reaches Key Milestone In Lilly Partnership For Diabetes & Metabolic Disease Research | 509 | AFX News | INDIANAPOLIS (dpa-AFX) - Nxera Pharma Co., Ltd. announced that it has achieved a development milestone under its multi-target collaboration and license agreement with Eli Lilly and Co. (LLY)... ► Artikel lesen | |
| 02.06. | Nxera Pharma Achieves Development Milestone in Collaboration with Eli Lilly Targeting Metabolic Diseases | 183 | GlobeNewswire (Europe) | Tokyo, Japan and Cambridge, UK, 2 June 2025 - Nxera Pharma Co., Ltd. ("Nxera" or "the Company"; TSE 4565) today announces that it has achieved a development milestone under its multi-target collaboration... ► Artikel lesen | |
| 02.05. | Nxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2025 | 160 | GlobeNewswire (Europe) | Tokyo, Japan and Cambridge, UK, 2 May 2025 - Nxera Pharma ("the Company" or "Nxera"; TSE: 4565) provides an update on operational activities and reports its consolidated results for the first quarter... ► Artikel lesen | |
| 01.05. | Nxera Pharma's Partner Neurocrine Biosciences Initiates Phase 3 Registrational Program of NBI-1117568 as a Potential Treatment for Adults with Schizophrenia | 192 | GlobeNewswire (Europe) | NBI-1117568 is an oral, muscarinic M4 selective receptor agonist discovered by Nxera advancing through clinical development under a multi-program collaboration with NeurocrineFor more information... ► Artikel lesen | |
| NXERA PHARMA Aktie jetzt für 0€ handeln | |||||
| 01.05. | Nxera Pharma Appoints Top-Ranked Biopharma Investment Analyst Shinya Tsuzuki as Head of Investor Relations | 1 | GlobeNewswire (USA) | ||
| 03.04. | Nxera Pharma appoints AstraZeneca alum as inaugural commercial chief | 3 | FiercePharma | ||
| 01.04. | Nxera Pharma Announces Appointments to its Executive Leadership Team | 1 | GlobeNewswire (USA) | ||
| 25.03. | Nxera Pharma's Partner Tempero Bio Initiates Phase 2 Trial with TMP-301 for Alcohol Use Disorder | 296 | GlobeNewswire (Europe) | Tokyo, Japan and Cambridge, UK, 25 March 2025 - Nxera Pharma Co., Ltd. ("Nxera" or "the Company"; TSE 4565) announces that its partner Tempero Bio, Inc. has initiated a Phase 2 trial of TMP-301, a... ► Artikel lesen | |
| 28.02. | Nxera sells APAC license to lupus drug to Viatris for $10M upfront | 32 | FierceBiotech | ||
| 28.02. | Nxera Pharma Enters Agreement with Holling to Commercialize Daridorexant in Taiwan | 1 | GlobeNewswire (USA) | ||
| 28.02. | Nxera Pharma Assigns Japan and APAC (ex-China) Rights to Cenerimod for Autoimmune Diseases to Viatris | 30 | GlobeNewswire (USA) | ||
| 14.02. | Nxera Pharma Proposes Changes to its Board of Directors | 1 | GlobeNewswire (USA) | ||
| 14.02. | Nxera Pharma Operational Highlights and Consolidated Results for the Fourth Quarter and Full Year 2024 | 383 | GlobeNewswire (Europe) | Tokyo, Japan and Cambridge, UK, 14 February 2025 - Nxera Pharma Co., Ltd. ("Nxera" or "the Company"; TSE 4565) provides an update on operational activities and reports its consolidated results for... ► Artikel lesen | |
| 07.02. | Singtel's Nxera DCT bags $643m green loan for new data centre in Tuas | 2 | Singapore Business Review | ||
| 05.12.24 | Nxera Pharma Enrolls First Insomnia Patient in its Phase 3 Clinical Trial of Daridorexant in South Korea | 208 | GlobeNewswire (Europe) | Daridorexant is a dual orexin receptor antagonist being developed by Nxera for the treatment of adult patients with insomniaQUVIVIQ (daridorexant) 25 and 50 mg was recently approved and is expected... ► Artikel lesen | |
| 13.11.24 | Nxera Pharma's Partner Centessa Initiates Phase 2 Trial with ORX750, a Novel Orexin Receptor 2 (OX2R) Agonist | 353 | GlobeNewswire (Europe) | Phase 2 trial initiation in patients with sleep /wake disorders results in milestone payment of US$3.5 million to Nxera Tokyo, Japan and Cambridge, UK, 13 November 2024 - Nxera Pharma Co., Ltd. ("Nxera"... ► Artikel lesen |
1 2 Weiter >>
28 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PFIZER | 21,045 | +0,33 % | Dividendenbekanntmachungen (25.07.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ALBERTSONS COMPANIES INC US0130911037 0,15 USD 0,1276 EUR AVI GLOBAL TRUST PLC GB00BLH3CY60 0,015 GBP EUR BANK OF NEW YORK MELLON... ► Artikel lesen | |
| NOVARTIS | 100,18 | -0,04 % | UBS stuft NOVARTIS AG auf 'Neutral' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat das Kursziel für Novartis nach einem zweiten Blick auf die Zahlen von 104 auf 95 Franken gesenkt, aber die Einstufung auf "Neutral" belassen.... ► Artikel lesen | |
| GILEAD SCIENCES | 97,95 | +0,46 % | Gilead Sciences, Inc.: Gilead Receives Positive CHMP Opinions Under Accelerated Review From European Medicines Agency for Twice-Yearly Lenacapavir for HIV Prevention | - If Approved, Lenacapavir Would Be the First and Only Twice-Yearly HIV PrEP Option in the European Union - - Positive Opinion Also Received for EMA's EU-M4all Procedure, Designed to Facilitate... ► Artikel lesen | |
| SANOFI | 85,96 | +0,42 % | BERNSTEIN RESEARCH stuft SANOFI auf 'Outperform' | NEW YORK (dpa-AFX Analyser) - Das US-Analysehaus Bernstein Research hat Sanofi mit einem Kursziel von 124 Euro auf "Outperform" belassen. Der geplante Kauf der britischen Biotechfirma Vicebio werde... ► Artikel lesen | |
| ABBVIE | 163,40 | +0,37 % | Pre-Q2 Earnings: Is AbbVie Stock a Portfolio Must-Have? | ||
| ROCHE | 280,00 | +0,11 % | DEUTSCHE BANK RESEARCH stuft ROCHE HOLDINGS AG auf 'Sell' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Roche auf "Sell" mit einem Kursziel von 235 Franken belassen. Emmanuel Papadakis bezieht sich in einer am Dienstag vorliegenden... ► Artikel lesen | |
| ABBOTT LABORATORIES | 109,84 | +0,77 % | MedMira Zusammenfassung!: MedMira auf den Punkt gebracht! | ||
| HAEMATO | 10,800 | 0,00 % | M1 Kliniken: Verkauf von HAEMATO PHARM im Fokus | Die M1 Kliniken AG steht vor dem möglichen Verkauf eines Teils der Konzern-Aktivitäten: Die zur Gruppe gehörende HAEMATO AG prüft derzeit ein verbindliches Angebot für den Verkauf ihrer Tochtergesellschaft... ► Artikel lesen | |
| INCYTE | 60,36 | -0,33 % | Incyte präsentiert erste Daten für seinen TGFßR2×PD-1-gerichteten bispezifischen Antikörper (INCA33890) und seinen selektiven Inhibitor des G12D-mutierten KRAS (INCB161734) auf dem Kongress der European Society of Medical Oncology (ESMO) 2025 | Mündliche Kurzdarstellung zur Hervorhebung erster Phase-1-Daten zu INCA33890, einem vielversprechenden TGFßR2×PD-1-gerichteten bispezifischen Antikörper, bei Patienten mit fortgeschrittenen oder metastasierten... ► Artikel lesen | |
| EDWARDS LIFESCIENCES | 68,18 | +0,71 % | Edwards Lifesciences Corp. Reports Retreat In Q2 Income | WASHINGTON (dpa-AFX) - Edwards Lifesciences Corp. (EW) reported earnings for second quarter that Drops, from the same period last yearThe company's bottom line totaled $333.2 million, or $0.56... ► Artikel lesen | |
| WPD PHARMACEUTICALS | 0,002 | 0,00 % | WPD Pharmaceuticals Inc (2): WPD Pharmaceuticals suspended by CSE | ||
| HALEON | 4,200 | +0,57 % | Haleon Breaks Ground on new £130m Global Oral Health Innovation Centre | This week, Haleon, a global leader in consumer health and maker of leading brands such as Sensodyne, parodontax and Polident, broke ground on its new Global Oral Health Innovation Centre in Weybridge... ► Artikel lesen | |
| BIONANO GENOMICS | 3,290 | -2,95 % | Bionano Genomics: Bionano Reports First Quarter 2025 Results and Highlights Recent Business Progress | SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the first quarter ended March 31, 2025. "The first quarter of 2025 represents... ► Artikel lesen | |
| TONIX PHARMACEUTICALS | 41,200 | +0,49 % | Pre-market Movers: Creative Global Technology, Liminatus Pharma, CureVac, Jupiter Neurosciences, Tonix Pharmaceuticals | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.05 A.M. ET).In the Green Creative Global Technology Holdings Limited (CGTL)... ► Artikel lesen | |
| GRIFOLS | 12,695 | +0,99 % | XL-protein GmbH: XL-protein grants worldwide license to Grifols to develop a biopharmaceutical using PASylation(R) technology | Press Release: XL-protein grants worldwide license to Grifols to develop a biopharmaceutical using PASylation(R) technology
Freising, Germany, June 10, 2025 -- XL-protein GmbH, a pioneer in... ► Artikel lesen |
Das Unternehmen NXERA PHARMA CO LTD kann der Branche Pharma zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 4,920 Euro. Aus der Ausschüttung der letzten 12 Monate von insgesamt 0,00 Euro errechnet sich eine Dividendendrendite von 0,00 %.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NXERA PHARMA CO LTD finden Sie auf Wallstreet Online.